Supplements · Metabolic & Cardiometabolic
garlic slows atherosclerosis progression
In plain terms: Does aged garlic extract slow heart disease?
Part of: 🧪 Garlic
Too early to say. A few trials suggest aged garlic extract slows the buildup of coronary calcium — but nearly all come from one lab, on surrogate scan measures rather than actual heart attacks or deaths, and no trial has tested hard outcomes. Promising, not proven.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Aged garlic extract appears to slow surrogate markers of atherosclerosis (coronary-calcium and plaque progression, arterial stiffness). Most trials come from a single lab (Budoff/Harbor-UCLA) reanalyzing overlapping cohorts, but there is now independent replication - notably an independent Swedish CAC RCT (Wlosinska 2020) and a Polish arterial-stiffness RCT.
The evidence (22)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Varshney R, Budoff MJ 2016 · J Nutr | observational | mixed | low | Narrative review (Budoff co-author): AGE favorable on CAC/CRP/PWV; calls for larger trials. |
| Wlosinska M et al. 2020 · BMC Complement Med Ther | RCT | supports | moderate | INDEPENDENT RCT (Lund, Sweden): AGE 2400mg/d x1y slowed coronary-calcium progression, lowered IL-6/glucose/SBP. Surrogate imaging - first non-Budoff CAC trial. ↩ SUPERSEDED — pooled in the review above, counted once |
| Ahmadi N et al. 2010 · Am J Cardiol | RCT | mixed | low | Oxidative-stress biomarkers correlated with lower CAC progression (Budoff lab, mechanism). |
| Chao C et al. 2021 · Coron Artery Dis | RCT | mixed | low | Garlic-4 substudy (Budoff lab): new carotid plaque predicted coronary progression (surrogate). |
| Emamat H et al. 2020 · Clin Nutr | observational | mixed | moderate | INDEPENDENT systematic review 10 RCTs: garlic's effect on vascular reactivity/stiffness INCONSISTENT across trials. |
| Shaikh K et al. 2019 · Exp Ther Med | RCT | supports | low | AGE reduced low-attenuation coronary plaque in diabetics via CCTA (Budoff lab, surrogate). ↩ SUPERSEDED — pooled in the review above, counted once |
| Zeb I et al. 2012 · J Cardiovasc Dis Res | RCT | supports | low | AGE+CoQ10 lowered CAC progression 3.99-fold + CRP in firefighters (Budoff lab, surrogate). |
| Ahmadi N et al. 2013 · Int J Cardiol | RCT | mixed | low | AGE+S adipose shifts + no CAC progression (Budoff lab). |
| Matsumoto S et al. 2016 · J Nutr | RCT | supports | moderate | RCT (n=55, metabolic syndrome): 2400 mg/d aged garlic extract reduced low-attenuation coronary plaque on CCTA over 1 yr. Surrogate endpoint; SAME lab as Budoff (not independent). ↩ SUPERSEDED — pooled in the review above, counted once |
| Larijani VN et al. 2012 · Nutrition | RCT | supports | moderate | FAITH trial: AGE+CoQ10 improved pulse-wave velocity + endothelial function (Budoff lab, surrogate). |
| Myasoedova VA et al 2016 · study_type: RCT | RCT | mixed | moderate | Double-blind placebo-controlled RCT, n=157 postmenopausal women, 12 months, isoflavonoid-rich herbal preparation ('Karinat': garlic powder + grape-seed tannins + green-tea leaf + hop-cone powder, 500mg/d) vs placebo, carotid IMT endpoint. c |
| Murali S et al 2023 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review of 49 RCTs (n=9901 total) testing interventions against cardiovascular-calcification progression by radiological endpoint. Trials involving aged garlic extract (n=6 studies) 'consistently showed attenuation of cardiovascul |
| Orekhov AN et al 2013 · study_type: RCT | RCT | supports | moderate | AMAR (Atherosclerosis Monitoring and Atherogenicity Reduction) study: 2-yr RCT, time-released garlic drug Allicor vs placebo, n=196 asymptomatic men aged 40-74, carotid IMT by B-mode ultrasound. Allicor group IMT change -0.022±0.007 mm/yr v |
| Stabler SN, Tejani AM et al. 2012 · Cochrane Database Syst Rev | meta-analysis | tested-null | high | Cochrane review: NO RCTs met criteria for garlic's effect on hard cardiovascular morbidity/mortality - an evidence gap, not a positive finding. |
| Yang S et al 2024 · study_type: observational | observational | supports | moderate | Two-sample Mendelian Randomization using GWAS/IEU data found garlic intake causally associated with reduced atherosclerosis risk (OR=0.985, p=0.036) and lower LDL-C/triglycerides, the strongest atheroprotective association among 28 fruits/v |
| Szulinska M et al. 2018 · Biomed Pharmacother | RCT | supports | moderate | INDEPENDENT RCT (Poland): garlic 400mg/d x3mo reduced arterial stiffness, hsCRP, PAI-1, LDL in obese. Surrogate. |
| Zeb I et al. 2018 · Coron Artery Dis | RCT | mixed | low | AGE+supplements reduced peri-cardiac adipose progression (Budoff lab, surrogate). |
| Tang YY et al 2025 · study_type: in-vitro | in-vitro | supports | low | Alliin (garlic organosulfide) protected ox-LDL-injured HUVECs, upregulating LDLR/ApoC and downregulating ApoB in cholesterol metabolism pathway; proteomic/Western blot validation, no animal or human data. |
| Budoff MJ et al. 2009 · Prev Med | RCT | supports | moderate | RCT (n=65): aged garlic extract + B-vitamins/folate/L-arginine slowed 1-yr coronary-calcium progression vs placebo. Surrogate imaging; single lab (Harbor-UCLA), Kyolic-funded. ↩ SUPERSEDED — pooled in the review above, counted once |
| Schwingshackl L et al. 2015 · Phytomedicine | observational | supports | moderate | INDEPENDENT umbrella review: garlic lowers TC and BP consistently, but no atherosclerosis-imaging endpoint (risk-factor surrogate only). |
| Budoff MJ et al. 2004 · Prev Med | RCT | supports | low | Founding pilot n=19: AGE slowed EBT coronary-calcium progression in statin patients (Budoff lab). ↩ SUPERSEDED — pooled in the review above, counted once |
| Gao T et al 2024 · study_type: animal | animal | supports | moderate | ApoE-knockout mouse model plus network pharmacology; garlic active components (Allicin, alliin, etc.) reduced ferroptosis-related gene expression and intra-plaque lipid peroxidation, with in vitro validation of core targets (DPP4, ALOX5, GP |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.